Genetic testing company anticipates exceeding estimates

  • Myriad Genetics expects fourth-quarter revenue to exceed expectations
  • Preliminary results show revenue of $196 million to $197 million
  • Per-share loss forecasted to be 35 cents to 36 cents
  • Adjusted profit anticipated to be 2 cents to 3 cents per share
  • Full-year revenue expected to increase by at least 10%

Myriad Genetics, a Salt Lake City-based genetic testing company, is set to surpass expectations with its fourth-quarter revenue. Preliminary results indicate revenue of $196 million to $197 million, outperforming the estimated $194.8 million. The company also forecasts a per-share loss of 35 cents to 36 cents, compared to a 52-cent loss in the previous year. However, an adjusted profit of 2 cents to 3 cents per share is expected, surpassing the estimated 1 cent. Myriad Genetics also projects a full-year revenue increase of at least 10%, in line with its previous guidance for 10% to 11% growth over 2022.

Public Companies: Myriad Genetics (N/A)
Private Companies:
Key People:

Factuality Level: 8
Justification: The article provides specific information about Myriad Genetics’ expected fourth-quarter revenue and compares it to analysts’ expectations. It also includes information about the company’s per-share loss and adjusted profit. The information is based on a regulatory filing and analyst polls, which adds credibility to the report. However, it would be more comprehensive if it included additional context about the company’s performance and the factors contributing to the expected results.

Noise Level: 3
Justification: The article provides straightforward information about Myriad Genetics’ expected fourth-quarter revenue and earnings. It includes data from a regulatory filing and compares it to analysts’ expectations. The article stays on topic and does not dive into unrelated territories. However, it lacks in-depth analysis, antifragility considerations, and accountability of powerful people. It also does not provide actionable insights or solutions.

Financial Relevance: Yes
Financial Markets Impacted: Myriad Genetics

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article provides financial information about Myriad Genetics, including their fourth-quarter revenue expectations and per-share loss. There is no mention of an extreme event.

Reported publicly: www.marketwatch.com